Activating the innate immune response to counter chronic hepatitis B virus infection

References

• Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. New England J Med. 1975;292(15):771–774. DOI:10.1056/NEJM197504102921503
   PubMed Web of Science ®Google Scholar
• Maupas P, Coursaget P, Goudeau A, et al. Immunisation against hepatitis B in man. The Lancet. 1976;307(7974):1367–1370. DOI:10.1016/S0140-6736(76)93023-3
   Google Scholar
• Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2015;204(1):39–55. DOI:10.1007/s00430-014-0373-y
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B virus Fact sheet No. 204; 2013 [Updated 2016 July]. [cited 2016 Jul 31]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/index.html
   Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273. DOI:10.1053/j.gastro.2011.12.061
   PubMed Web of Science ®Google Scholar
• Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology. 2013 Mar;57(3):985–994. DOI:10.1002/hep.26125
   PubMed Web of Science ®Google Scholar
• Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049. DOI:10.7554/eLife.00049
   PubMed Web of Science ®Google Scholar
• Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014 Apr;146(4):1070–1083. DOI:10.1053/j.gastro.2013.12.024
   PubMed Web of Science ®Google Scholar
• Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015 Dec;64(12):1972–1984. DOI:10.1136/gutjnl-2015-309809
   PubMed Web of Science ®Google Scholar
• Ducroux A, Benhenda S, Riviere L, et al. The tudor domain protein spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B virus and herpes simplex virus type 1. PLoS Pathog. 2014 Sep;10(9):e1004343. DOI:10.1371/journal.ppat.1004343
   Google Scholar
• Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009 Sep;51(3):581–592. DOI:10.1016/j.jhep.2009.05.022
   PubMed Web of Science ®Google Scholar
• Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology. 2006 Mar;130(3):823–837. DOI:10.1053/j.gastro.2006.01.001
   PubMed Web of Science ®Google Scholar
• Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9(5):679–693.
   PubMed Web of Science ®Google Scholar
• Perrillo RP Current treatment of chronic hepatitis B: benefits and limitations. Seminars in liver disease; 2005. Georg Thieme Verlag; 2005. p. 20. DOI:10.1055/s-2005-915647
   Google Scholar
• Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther. 2010;15(Suppl 3):3–14. DOI:10.3851/IMP1619
   PubMed Web of Science ®Google Scholar
• Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8(5):275–284. DOI:10.1038/nrgastro.2011.33
   PubMed Web of Science ®Google Scholar
• Revill P, Testoni B, Locarnini S, et al. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):239–248. DOI:10.1038/nrgastro.2016.7
   PubMed Web of Science ®Google Scholar
• Chen GD, Gu JL, Qiu J, et al. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers. Transpl Infect Dis. 2013 Jun;15(3):300–305. DOI:10.1111/tid.12065
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015 Oct;22(10):842–849. DOI:10.1111/jvh.12402
   PubMed Web of Science ®Google Scholar
• Sato S, Li K, Kameyama T, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity. 2015;42(1):123–132. DOI:10.1016/j.immuni.2014.12.016
   PubMed Web of Science ®Google Scholar
• Shlomai A, Schwartz RE, Ramanan V, et al. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci USA. 2014 Aug 19;111(33):12193–12198.
   PubMed Web of Science ®Google Scholar
• Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology. 2009;137(4):1289–1300. DOI:10.1053/j.gastro.2009.06.054
   PubMed Web of Science ®Google Scholar
• Wieland S, Thimme R, Purcell RH, et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA. 2004 Apr 27;101(17):6669–6674.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009;49(4):1132–1140. DOI:10.1002/hep.22751
   PubMed Web of Science ®Google Scholar
• Yu S, Chen J, Wu M, et al. Hepatitis B virus polymerase inhibits RIG-I-and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKε and DDX3. J Gen Virol. 2010;91(8):2080–2090. DOI:10.1099/vir.0.020552-0
   PubMed Web of Science ®Google Scholar
• Liu Y, Li J, Chen J, et al. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol. 2015;89(4):2287–2300. DOI:10.1128/JVI.02760-14
   PubMed Web of Science ®Google Scholar
• Lütgehetmann M, Bornscheuer T, Volz T, et al. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology. 2011;140(7):2074–2083. e2. DOI:10.1053/j.gastro.2011.02.057
   PubMed Web of Science ®Google Scholar
• Luangsay S, Gruffaz M, Isorce N, et al. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015;63(6):1314–1322. DOI:10.1016/j.jhep.2015.07.014
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol. 2015 Oct;36:61–66. DOI:10.1016/j.coi.2015.06.016
   PubMed Web of Science ®Google Scholar
• Isogawa M, Chung J, Murata Y, et al. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013;9(7):e1003490. DOI:10.1371/journal.ppat.1003490
   Web of Science ®Google Scholar
• Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol. 2005 Mar;79(5):3016–3027. DOI:10.1128/JVI.79.5.3016-3027.2005
   PubMed Web of Science ®Google Scholar
• Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002 May 6;195(9):1089–1101.
   PubMed Web of Science ®Google Scholar
• Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 2010;6(12):e1001227. DOI:10.1371/journal.ppat.1000975
   Google Scholar
• Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol. 2016;64(1):S60–S70. DOI:10.1016/j.jhep.2016.01.028
   Google Scholar
• Doherty DG, Norris S, Madrigal-Estebas L, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+ CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol. 1999;163(4):2314–2321.
   PubMed Web of Science ®Google Scholar
• Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage. J Exp Med. 2007;204(3):667–680. DOI:10.1084/jem.20061287
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology. 2009;137(3):1151–1160. e7. DOI:10.1053/j.gastro.2009.05.047
   PubMed Web of Science ®Google Scholar
• Peppa D, Gill US, Reynolds G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion. J Exp Med. 2013;210(1):99–114. DOI:10.1084/jem.20121172
   PubMed Web of Science ®Google Scholar
• Zeissig S, Murata K, Sweet L, et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med. 2012;18(7):1060–1068. DOI:10.1038/nm.2811
   PubMed Web of Science ®Google Scholar
• Tang X-Z, Jo J, Tan AT, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol. 2013;190(7):3142–3152. DOI:10.4049/jimmunol.1203218
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Seidler S, Nattermann J, et al. Functional contribution of elevated circulating and hepatic non-classical CD14+ CD16+ monocytes to inflammation and human liver fibrosis. Plos One. 2010;5(6):e11049. DOI:10.1371/journal.pone.0011049
   PubMed Web of Science ®Google Scholar
• Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60(5):1090–1096. DOI:10.1016/j.jhep.2013.12.025
   PubMed Web of Science ®Google Scholar
• Heymann F, Peusquens J, Ludwig‐Portugall I, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62(1):279–291. DOI:10.1002/hep.27793
   PubMed Web of Science ®Google Scholar
• Li M, Sun R, Xu L, et al. Kupffer cells support hepatitis B virus–mediated CD8+ T cell exhaustion via hepatitis B core antigen–TLR2 interactions in mice. J Immunol. 2015;195(7):3100–3109. DOI:10.4049/jimmunol.1500839
   PubMed Web of Science ®Google Scholar
• Pallett LJ, Gill US, Quaglia A, et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med. 2015;21(6):591–600. DOI:10.1038/nm.3856
   PubMed Web of Science ®Google Scholar
• Kong X, Sun R, Chen Y, et al. γδT cells drive myeloid-derived suppressor cell–mediated CD8+ T cell exhaustion in hepatitis B virus–induced immunotolerance. J Immunol. 2014;193(4):1645–1653. DOI:10.4049/jimmunol.1303432
   PubMed Web of Science ®Google Scholar
• Chou HS, Hsieh CC, Yang HR, et al. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011;53(3):1007–1019. DOI:10.1002/hep.24162
   PubMed Web of Science ®Google Scholar
• Fang Z, Li J, Yu X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis B surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection. J Immunol. 2015;195(10):4873–4883. DOI:10.4049/jimmunol.1501362
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. DOI:10.1016/j.cell.2006.02.015
   PubMed Web of Science ®Google Scholar
• Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204(1):11–20. DOI:10.1007/s00430-014-0370-1
   PubMed Web of Science ®Google Scholar
• McClary H, Koch R, Chisari FV, et al. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol. 2000;74(5):2255–2264.
   PubMed Web of Science ®Google Scholar
• Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol. 2000;74(9):4165–4173.
   PubMed Web of Science ®Google Scholar
• Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005;79(11):7269–7272. DOI:10.1128/JVI.79.11.7269-7272.2005
   PubMed Web of Science ®Google Scholar
• Cui X, Clark DN, Liu K, et al. Viral DNA-dependent induction of innate immune response to hepatitis B virus in immortalized mouse hepatocytes. J Virol. 2016;90(1):486–496. DOI:10.1128/JVI.01263-15
   Web of Science ®Google Scholar
• Cooper A, Tal G, Lider O, et al. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol. 2005;175(5):3165–3176.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng Z, Jiang M, et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology. 2010;129(3):363–374. DOI:10.1111/j.1365-2567.2009.03179.x
   PubMed Web of Science ®Google Scholar
• Shi B, Ren G, Hu Y, et al. HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. PLoS One. 2012;7(9):e44900. DOI:10.1371/journal.pone.0044900
   Google Scholar
• Wu M, Xu Y, Lin S, et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol. 2007;88(12):3260–3269. DOI:10.1099/vir.0.82959-0
   PubMed Web of Science ®Google Scholar
• Chen J, Wu M, Zhang X, et al. Hepatitis B virus polymerase impairs interferon-α–induced STA T activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology. 2013;57(2):470–482. DOI:10.1002/hep.26064
   PubMed Web of Science ®Google Scholar
• Kumar M, Jung SY, Hodgson AJ, et al. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol. 2011;85(2):987–995. DOI:10.1128/JVI.01825-10
   PubMed Web of Science ®Google Scholar
• Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol. 2010;185(2):1158–1168. DOI:10.4049/jimmunol.0903874
   PubMed Web of Science ®Google Scholar
• Iannacone M, Guidotti LG. Hepatitis B virus immunopathogenesis. Hepatitis B Virus in Human Diseases. Springer 2016:79–93. DOI:10.4103/0970-0218.169685
   Google Scholar
• Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015 Jun;62(6):1237–1245. DOI:10.1016/j.jhep.2014.12.026
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013;144(7):1508–1517. e10. DOI:10.1053/j.gastro.2013.02.003
   PubMed Web of Science ®Google Scholar
• Gane EJ, Lim Y-S, Gordon SC, et al., The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 63(2): 320–328. 2015. DOI:10.1016/j.jhep.2015.02.037
   PubMed Web of Science ®Google Scholar
• Fontaine H, Kahi S, Chazallon C, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN. Gut. 2015 Jan;64(1):139-147 gutjnl-2013-305707.
   PubMed Web of Science ®Google Scholar
• Raney AK, Eggers CM, Kline EF, et al. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J Virol. 2001 Mar;75(6):2900–2911. DOI:10.1128/JVI.75.6.2900-2911.2001
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci. 1994;91(9):3764–3768. DOI:10.1073/pnas.91.9.3764
   PubMed Web of Science ®Google Scholar
• Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012 Feb;122(2):529–537. DOI:10.1172/JCI58847
   PubMed Web of Science ®Google Scholar
• Pasquetto V, Wieland SF, Uprichard SL, et al. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol. 2002 Jun;76(11):5646–5653.
   PubMed Web of Science ®Google Scholar
• Rang A, Gunther S, Will H. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol. 1999 Nov;31(5):791–799.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 343(6176): 1221–1228. 2014. 10.1126/science.1243462
   PubMed Web of Science ®Google Scholar
• Fosdick A, Zheng J, Pflanz S, et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96–105. DOI:10.1124/jpet.113.207878
   PubMed Web of Science ®Google Scholar
• Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15(8):471–485. DOI:10.1038/nri3865
   PubMed Web of Science ®Google Scholar
• Oh JZ, Kurche JS, Burchill MA, et al. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood. 2011;118(11):3028–3038. DOI:10.1182/blood-2011-04-348839
   PubMed Web of Science ®Google Scholar
• Jo J, Tan AT, Ussher JE, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. 2014;10(6):e1004210. DOI:10.1371/journal.ppat.1004210
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526–1529. DOI:10.1126/science.1093620
   PubMed Web of Science ®Google Scholar
• Demaria O, Pagni PP, Traub S, et al. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest. 2010;120(10):3651–3662. DOI:10.1172/JCI42081
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen K, Wu Z, et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice. Int J Infect Dis. 2014 Dec;29:31–36. DOI:10.1016/j.ijid.2014.07.015
   PubMed Web of Science ®Google Scholar
• Wu J, Huang S, Zhao X, et al. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol. 2014 Sep;88(18):10421–10431. DOI:10.1128/JVI.00996-14
   PubMed Web of Science ®Google Scholar
• Guo F, Han Y, Zhao X, et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother. 2015 Feb;59(2):1273–1281. DOI:10.1128/AAC.04321-14
   PubMed Web of Science ®Google Scholar
• Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013 Jan;14(1):19–26. DOI:10.1038/ni.2491
   PubMed Web of Science ®Google Scholar
• Wang L, Zou ZQ, Liu CX, et al. Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. J Immunol Methods. 2014;407:1–8. DOI:10.1016/j.jim.2014.04.004
   PubMed Web of Science ®Google Scholar
• Isorce N, Lucifora J, Zoulim F, et al. Immune-modulators to combat hepatitis B virus infection: from IFN-α to novel investigational immunotherapeutic strategies. Antiviral Res. 2015;122:69–81. DOI:10.1016/j.antiviral.2015.08.008
   PubMed Web of Science ®Google Scholar
• Chou YC, Chen ML, Hu CP, et al. Transforming growth factor‐β1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology. 2007;46(3):672–681. DOI:10.1002/hep.21726
   PubMed Web of Science ®Google Scholar
• Zhang -Y-Y, Chen E-Q, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6(1):1. DOI:10.1186/1743-422X-6-19
   PubMed Web of Science ®Google Scholar
• Schurich A, Pallett LJ, Lubowiecki M, et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog. 2013;9(3):e1003208. DOI:10.1371/journal.ppat.1003208
   PubMed Web of Science ®Google Scholar
• Ely A, Moyo B, Arbuthnot P. Progress with developing use of gene editing to cure chronic infection with hepatitis B virus. Mol Ther. 2016 Feb 26;24(4):671–677. DOI:10.1038/mt.2016.43
   PubMed Web of Science ®Google Scholar
• Schiffer JT, Aubert M, Weber ND, et al. Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol. 2012 Sep;86(17):8920–8936. DOI:10.1128/JVI.00052-12
   PubMed Web of Science ®Google Scholar
• Lopatin U, Wolfgang G, Tumas D, et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther. 2013;18(3):409–418. DOI:10.3851/IMP2548
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–684. DOI:10.1002/hep.21282
   PubMed Web of Science ®Google Scholar